news
Telomir-Zn inhibits bone cancer cells in early lab study
In a preclinical in vitro study, Telomir-Zn inhibited cell growth in human and canine osteosarcoma models. The research, a collaboration between Telomir and The Ohio State University, found dose-dependent anti-tumor activity across three cell lines.
In a preclinical in vitro study, Telomir-Zn inhibited cell growth in human and canine osteosarcoma models. The research, a collaboration between Telomir and The Ohio State University, found dose-dependent anti-tumor activity across three cell lines.
The architecture take
I keep seeing research on zinc and longevity markers, and now this: a specific zinc formulation, Telomir-Zn, looks like it can put the brakes on bone cancer cell growth. The initial in vitro findings, led by Shay Bracha at Ohio State, show it's dose-dependent, meaning more zinc, more inhibition. This isn't a human trial yet, it's just cells in a dish, but the mechanism is intriguing. If zinc can slow down cancerous replication, especially in a nasty cancer like osteosarcoma, it opens up a whole new angle on how micronutrients might actually influence fundamental cellular health and potentially biological aging. Most people aren't thinking about their zinc intake for cancer prevention, but maybe they should be. I'm watching to see if this moves to animal studies next, and what dosage they eventually land on.